The company's ophthalmologic tests can help affected patients and family members guide disease management to prevent vision loss, blindness, and complications from eye surgery.
Its pharmacogenomic test predicts patient reactions to drugs in order to reduce risk of adverse events.
The most common retinal disorder on the ophthalmologic test, retinitis pigmentosa, claims an incidence rate of 1 in 3.5 thousand individuals, with other conditions tested exhibiting high incidence rates as well.
Similarly, genetic factors also account for 20-95% of variability in response to individual drugs, with 10-20% of adverse drug reactions potentially related to genetic factors.
The company's new tests include the most comprehensive panels of genes based on the latest advances in research.
Phosphorus said its panels, data analytics, and variant interpretations have been designed and developed to ensure the most accurate results for patients. The tests are powered by next-generation sequencing technology, including detection of copy number variants.
The simple testing workflow is designed to ease the process for physicians and provide an affordable option for patients and their family members.
The newly launched ophthalmology genetic test covers retinal disorders, cataracts, glaucoma, and corneal dystrophy.
The newly launched drug response genetic test covers the most commonly prescribed drugs across a large cross section of therapeutic areas, including cardiology, psychiatry, oncology, pain management, neurology, immunology, gastroenterology, respiratory, infectious disease, and others.
Phosphorus offers clinical genetic tests in a range of clinical areas from its CLIA-certified laboratory.
The company also develops software that enables labs around the world to deliver the most advanced genetic tests. Phosphorus' active R and D programme has an initial focus on decoding the genetic causes of infertility and inherited cardiovascular disease.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
D3 Bio announces Series A+ Round completion to advance innovative oncology pipeline
Dizal's sunvozertinib receives US FDA Breakthrough Therapy Designation
Merck launches Phase 3 trial of MK-1084 and KEYTRUDA combination in metastatic NSCLC
Trevi Therapeutics names new vice president of Clinical Development
Personalis validates NeXT Personal test for ultra-sensitive MRD detection
Merck reports lung cancer trial failed to meet endpoints
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib